BioCatalystWatch
MRKRWorkspace / MRKR / OverviewCompany library
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc.

Marker Therapeutics, Inc. (MRKR)

Website

Price
Market cap
Next catalystExpected 2026MT-601 (Neldaleucel) · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

MT-601 (Neldaleucel)

Survivin × PRAME × WT1 × NY-ESO-1 × SSX-2 × MAGE-A4

PreINDP2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

MT-601 (Neldaleucel)

Survivin × PRAME × WT1 × NY-ESO-1 × SSX-2 × MAGE-A4

PreINDP2P3FilingApproved
Upcoming / outlook

Other pipelines

MT-401

PRAME × NY-ESO-1 × Survivin × WT1

PreINDP1P2P3FilingApproved
MT-401-OTS

WT1 × Survivin × PRAME × NY-ESO-1

PreINDP1P2P3FilingApproved
MT-601 (Neldaleucel)

Survivin × PRAME × WT1 × NY-ESO-1 × SSX-2 × MAGE-A4

PreINDP1P2P3FilingApproved

Partner / License out

MT-401

PRAME × NY-ESO-1 × Survivin × WT1

PreINDP1P2P3FilingApproved

History / paused

MT-401

PRAME × NY-ESO-1 × Survivin × WT1

PreINDP1P2P3FilingApproved

Folate Receptor Alpha (FRα)

PreINDP1P2P3FilingApproved

Folate Receptor Alpha (FRα)

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MRKR PR & News

PR & News

MRKR SEC archive